ClinicalTrials.gg

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Program

Anti-integrin Beta-6 Antibody-drug Conjugate PF-08046876

In Pfizer’s pipeline, Integrin beta-6-directed antibody-drug conjugate. Its studies are mostly in Urinary Bladder Neoplasms, led by Pfizer.

Furthest: phase 1, since Jul 21, 20251 company-led study, 1 open or runningNext primary completion: Jul 8, 2028 (phase 1)

Who develops it

Each company that leads studies of it, as its sponsor page counts them.

CompanyStudies it leadsFurthest phaseFirst studyNext primary completion
Pfizer11 open or runningphase 1since Jul 21, 2025Jul 21, 2025Jul 8, 2028phase 1 · NCT07090499
  • Named in Pfizer’s own pipeline as PF-08046876, phase 1, as of Nov 3, 2026 (source).

History and what’s ahead

From the studies’ own records, by the day each was first submitted. Purple marks an event: a company’s first study, a phase reached, a study stopped, a primary completion moved later (stops and moved dates are recorded from Sep 25, 2026). Dates ahead are the sponsors’ estimates.

  1. Jul 21, 2025First study: phase 1 study in Urinary Bladder NeoplasmsFirst studyNCT07090499 · 540 planned · United States, Canada, China and more

Ahead

  1. Jul 8, 2028Primary completion: phase 1 study in Urinary Bladder NeoplasmsNCT07090499

TargetBeta

“Integrin beta-6-directed antibody-drug conjugate”the company's pipeline, read by Claude · source
“An antibody-drug conjugate (ADC) composed of a monoclonal antibody directed against integrin beta-6 (IB6) conjugated, via a cleavable glucuronide linker, to the camptothecin analog, 7-aminomethyl-10,11-methylenedioxycamptothecin (AMDCPT), with potential antineoplastic activity. Upon administratio…”NCIt, read by Claude

Other programs on ITGB6

ProgramCompanyFurthest phaseStudies
sigvotatug vedotinPfizerphase 34
Anti-integrin Beta-6/MMAE Antibody-drug Conjugate PF-08052667Pfizerphase 11

Studies

All 1 led by companies developing it, newest first. Each opens its study page.

StudyPhaseStatusPrimary completionSize
NCT07090499Urinary Bladder Neoplasms · United States, Canada, China and more1RecruitingJul 8, 2028540

How it is read

Names in the registry

  • “PF-08046876”, 1 entry

Conditions, from the studies’ own filings

First seen by our ledger Nov 13, 2026.

What this can’t show

  • Only studies on ClinicalTrials.gov. Studies only in China’s, Europe’s or other registries are missing here.
  • Deals, prices and results are not in the registry. A licence or acquisition shows only with a dated source.
  • Primary completion dates are the sponsors’ estimates and often move.
  • A study counts here when it names this program among the drugs it tests; one that writes it only beside a placebo may be missed.